Interstitial lung disease in idiopathic inflammatory myopathy

Current Rheumatology Reviews

Volumn 6, Issue 2, 2010, Pages 108-119

  Saketkoo, Lesley Ann ^a,b   Ascherman, Dana P ^c   Cottin, Vincent ^d   Christopher Stine, Lisa ^e   Danoff, Sonye K ^e   Oddis, Chester V ^c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University Cancer Institute   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d HOSPICES CIVILS DE LYON   (France)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Interstitial lung disease; Myopathy; Myositis; Polymyositis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; COTRIMOXAZOLE; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKERATIN 19 FRAGMENT; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN; IMMUNOGLOBULIN; INFLUENZA VACCINE; KREBS VON DEN LUNDGEN 6; MENINGOCOCCUS VACCINE; METHOTREXATE; MI 2 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; RITUXIMAB; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SYNTHETASE AUTOANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION PNEUMONIA; BREATHING MUSCLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSCOPY; CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPOVENTILATION; IDIOPATHIC INFLAMMATORY MYOPATHY; INFLUENZA; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MENINGOCOCCOSIS; MUSCLE WEAKNESS; MYOSITIS; OPPORTUNISTIC INFECTION; OXYGEN THERAPY; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMOMEDIASTINUM; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; T LYMPHOCYTE; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

EID: 77956589927     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339710791330740     Document Type: Article

References (111)

1. Mills ES, Mathews WH. Interstitial pneumonitis in dermatomyositis. J Am Med Assoc 1956; 160(17): 1467-70.
2. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59(5): 677-85.
3. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63(3): 297-301.
4. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 459-67.
5. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44(10): 1282-6.
6. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 2006; 28(5): 1005-12.
7. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63(1): 53-9.
8. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28(5): 893-6.
9. Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009; 103(11): 1719-24.
10. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103(8): 1152-8.
11. Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135(6): 1550-6.
12. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17(6): 701-6.
13. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47(6): 614-22.
14. Chen, IJ, Jan WYJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28(6): 639-46.
15. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60(7): 2183-92.
16. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995; 38(10): 1519-23.
17. Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008; 31(1): 213-7.
18. Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136(5): 1341-7.
19. Polosa R, Di Mauro C, Spampinato B, et al. A patient with antihistidyl-tRNA synthetase positive polymyositis presenting as acute respiratory distress syndrome. J Clin Rheumatol 2008; 14(4): 219-21.
20. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin Rheumatol 2007; 26(10): 1647-54.
21. Tsuda T, Asanuma Y, Koyama S, Kawabata Y, Moriguchi M. A case of hypomyopathic dermatomyositis associated with rapid progressive interstitial pneumonia resistant to multi-immunosuppressive therapy. Am J Med Sci 2007; 333(3): 185-90.
22. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32(1): 58-64.
23. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157(4): 637-44.
24. Kobayashi I, Yamada M, Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: Clinical features and efficacy of cyclosporin A. Rheumatology 2003; 43: 371-4.
25. Morinishi Y, Oh-Ishi T, Kabuki T, Joh K. Juvenile dermatomyositis: Clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007; 17: 413-7.
26. Wilsher M, Wells AU. Pulmonary screening in patients with connective tissue disease prior to initiation of disease modifying drugs. Personal communication dated 6 June 2009.
27. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164(7): 1182-5.
28. Legault D, McDermott J, Crous-Tsanaclis AM, Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008; 35(1): 169-71.
29. Rozelle A, Trieu S, Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol 2008; 14(5): 285-8.
30. Marie I, Lahaxe L, Benveniste O, et al. Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162(2): 337-44.
31. Chinoy H, Salway F, Fertig N, Oddis CV, Ollier WE, Cooper RG. Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009; 48(5): 591-2.
32. Chinoy H, Salway F, Fertig N, et al. UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8(1): R13.
33. O'Hanlon TP, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006; 54: 3670-81.
34. Chinoy H, Payne D, Poulton KV, et al. UK Adult Onset Myositis Immunogenetic Collaboration & UK Juvenile Dermatomyositis Research Group. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009; 48(10): 1213-7.
35. O'Hanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008; 58(10): 3239-46.
36. Englund P, Wahlström J, Fathi M, et al. Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007; 56(1): 372-83.
37. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69: 2008-19.
38. Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56(11): 3784-92.
39. Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 2001; 21(3): 89-93.
40. Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002; 129(3): 541-8.
41. Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999; 14(2): 251-7.
42. Helmers SB, Englund P, Engström M, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum 2009; 60(8): 2524-30.
43. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46(1): 124-30.
44. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65(12): 1635-8.
45. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50(1): 209-15.
46. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70(6): 360-74.
47. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52(5): 1571-6.
48. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009; 29(9): 989-94.
49. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39(3): 249-53.
50. Limaye VS, Cassidy J, Scott G, Roberts-Thomson PJ, Gillis D. Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome. Clin Rheumatol 2008; 27(4): 521-3.
51. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9(4): R78.
52. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22(2): 245-50.
53. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54(4): 597-613.
54. Schmidt WA, Wetzel W, Friedländer R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations. Clin Rheumatol 2000; 19(5): 371-7.
55. Won HJ, Soon KD, Keun LC, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101(8): 1761-9.
56. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connective tissue diseases. Clin Chest Med 2008; 29(1): 149-64, vii.
57. Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: A similar condition? J Rheumatol 2010. [Epub ahead of print].
58. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum antibody to the nucleolar antigen PM-Scl: Clinical and immunogenetic associations. Arthritis Rheum 1992; 25: 1211-17.
59. Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53(2): 155-65.
60. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/ dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23(7): 1186-8.
61. Viguier M, Fouere S, de la Salmoniere P, et al. Peripheral blood lymphocyte subset counts in patient with dermatomyositis: Clinical correlations and changes following therapy. Medicine (Baltimore) 2003; 82-6.
62. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38(8): 616-23.
63. Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: Analysis of a series of 81 patients. Lupus 2005; 14(7): 534-42.
64. Goff BL, Chérin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61(1): 108-18.
65. Devaraj, Anand W, Athol U. Hansell, David M. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med 2007; 28: 389-97.
66. Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: A study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179(5): 408-13.
67. Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158(6): 1804-8.
68. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11: 452.
69. Minai OA. Pulmonary hypertension in polymyositis-dermatomyositis: Clinical and hemodynamic characteristics and response to vasoactive therapy. Lupus 2009; 18(11): 1006-10.
70. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S.
71. Daimon T, Johkoh T, Honda O, et al. Nonspecific interstitial pneumonia associated with collagen vascular disease: Analysis of CT features to distinguish the various types. Intern Med 2009; 48(10): 753-61.
72. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: Serial high-resolution CT findings and functional correlation. Chest 2003; 123(4): 1096-103.
73. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: Idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167: 1410-15.
74. Bouros D, Wells AU, Nicholson AG, et al. Histopathological subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-86.
75. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004; 49(3): 235-44.
76. Mochimaru H, Kawamoto M, Enomoto T, et al. Transbronchial biopsy is clinically useful in classifying patients with interstitial pneumonia associated with polymyositis and dermatomyositis. Respirology 2008; 13(6): 863-70.
77. Gregory SA. Evaluation and management of respiratory muscle dysfunction in ALS. NeuroRehabilitation 2007; 22(6): 435-43.
78. Nakayama M, Satoh H, Ishikawa H, et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 2003; 123(6): 2001-6.
79. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent Mortality in patients with interstitial lung diseases. J Intern Med 2006; 260(5): 429-34.
80. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165(3): 378-81.
81. Fujita J, Dobashi N, Tokuda M, et al. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis. J Rheumatol 1999; 26: 2377-82.
82. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004; 59(7): 581-5.
83. Grundtman C, Tham E, Ulfgren AK, Lundberg IE. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008; 58(10): 3224-38.
84. Martinez FJ, Safrin S, Weycker D, et al. IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142(12 Pt 1): 963-7.
85. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54(6): 2004-9.
86. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32 (9): 1719-26.
87. Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 2000; 39 (5): 428-30.
88. Bongartz T, Ryu JH, Matteson EL. Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease? Nat Clin Pract Rheumatol 2005; 1(2): 80-1.
89. Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999; 26(7): 1527-33.
90. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353(9166): 1762-3.
91. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38(5): 383-92.
92. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52(8): 2439-46.
93. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007; 321: 583-9.
94. Hervier B, Masseau A, Mussini JM, Audrain M, Hamidou MA. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 2009; 76(5): 575-6.
95. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337(5): 329-35.
96. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130(1): 30-6.
97. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65(7): 974-5.
98. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32(7): 1369-70.
99. Levine TD. Rituximab in treatment of dermatomyositis: an openlabel pilot study. Arthritis Rheum 2005; 52(2): 601-7.
100. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: A retrospective case series. Rheumatology (Oxford) 2009; 48(8): 968-71.
101. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29(12): 1499-502.
102. Krystufková O, Vallerskog T, Helmers SB, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009; 68(6): 836-43.
103. Cherin P, Pelletier S, Teixeira A, et al. Results and longterm follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467-74.
104. Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the aanem AD HOC committee. Muscle Nerve 2009; 40(5): 890-900.
105. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187(3): 201-6.
106. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156: 600-8.
107. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005; 37(1): 2-12.
108. Raghu G, King Jr TE, Behr J, et al. Impact of bosentan on healthrelated quality of life and dyspnoea in idiopathic pulmonary fibrosis: The BUILD-1 trial. Eur Respir J 2009. Epub 2009.
109. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 2001; 116: 417-25.
110. King TE Jr, Behr J, Brown KK, et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177(1): 75-81.
111. Pickering LK, Baker CJ, Freed GL, et al. Infectious Diseases Society of America. Immunization programs for infants, children, adolescents, and adults: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(6): 817-40.